DPP4 and diabetes mellitus: To compare the efficacy of SGLT2 inhibitors, GLP1 receptor analogues and DPP4 inhibitors on glycated haemoglobin (HbA1c), body weight and cardiovascular outcomes in people with established type 2 diabetes by applying a network meta-analysis (NMA) of all relevant type 2 diabetes trials and calibrating to a selected target population from the Scottish diabetes register.